Carlos Brotons , Miguel Camafort , María del Mar Castellanos , Albert Clarà , Olga Cortés , Angel Diaz Rodriguez , Roberto Elosua , Manuel Gorostidi , Antonio M. Hernández , María Herranz , Soledad Justo , Carlos Lahoz , Pilar Niño , Vicente Pallarés-Carratalá , Juan Pedro-Botet , Antonio Pérez Pérez , Miguel Angel Royo-Bordonada , Rafael Santamaria , Ricard Tresserras , Alberto Zamora , Pedro Armario
{"title":"CEIPV对2021年新的欧洲心血管预防指南的评论","authors":"Carlos Brotons , Miguel Camafort , María del Mar Castellanos , Albert Clarà , Olga Cortés , Angel Diaz Rodriguez , Roberto Elosua , Manuel Gorostidi , Antonio M. Hernández , María Herranz , Soledad Justo , Carlos Lahoz , Pilar Niño , Vicente Pallarés-Carratalá , Juan Pedro-Botet , Antonio Pérez Pérez , Miguel Angel Royo-Bordonada , Rafael Santamaria , Ricard Tresserras , Alberto Zamora , Pedro Armario","doi":"10.1016/j.arteri.2022.03.003","DOIUrl":null,"url":null,"abstract":"<div><p>We present the Spanish adaptation of the 2021 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. The current guidelines besides the individual approach greatly emphasize on the importance of population level approaches to the prevention of cardiovascular diseases. Systematic global cardiovascular disease risk assessment is recommended in individuals with any major vascular risk factor. Regarding LDL-cholesterol, blood pressure, and glycemic control in patients with diabetes mellitus, goals and targets remain as recommended in previous guidelines. However, it is proposed a new, stepwise approach (steps 1 and 2) to treatment intensification as a tool to help physicians and patients pursue these targets in a way that fits patient profile. After step 1, considering proceeding to the intensified goals of step 2 is mandatory, and this intensification will be based on 10-year cardiovascular disease risk, lifetime cardiovascular disease risk and treatment benefit, comorbidities and patient preferences.</p><p>The updated SCORE algorithm ?SCORE2, SCORE2-OP? is recommended in these guidelines, which estimates an individual's 10-year risk of fatal and non-fatal cardiovascular disease events (myocardial infarction, stroke) in healthy men and women aged 40-89 years. Another new and important recommendation is the use of different categories of risk according to different age groups (<<!--> <!-->50, 50-69, ≥<!--> <!-->70 years).</p><p>Different flow charts of cardiovascular disease risk and risk factor treatment in apparently healthy persons, in patients with established atherosclerotic cardiovascular disease, and in diabetic patients are recommended. Patients with chronic kidney disease are considered high risk or very high-risk patients according to the levels of glomerular filtration rate and albumin-to-creatinine ratio. New lifestyle recommendations adapted to the ones published by the Spanish Ministry of Health as well as recommendations focused on the management of lipids, blood pressure, diabetes and chronic renal failure are included.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comentario del CEIPV a las nuevas Guías Europeas de Prevención Cardiovascular 2021\",\"authors\":\"Carlos Brotons , Miguel Camafort , María del Mar Castellanos , Albert Clarà , Olga Cortés , Angel Diaz Rodriguez , Roberto Elosua , Manuel Gorostidi , Antonio M. Hernández , María Herranz , Soledad Justo , Carlos Lahoz , Pilar Niño , Vicente Pallarés-Carratalá , Juan Pedro-Botet , Antonio Pérez Pérez , Miguel Angel Royo-Bordonada , Rafael Santamaria , Ricard Tresserras , Alberto Zamora , Pedro Armario\",\"doi\":\"10.1016/j.arteri.2022.03.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>We present the Spanish adaptation of the 2021 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. The current guidelines besides the individual approach greatly emphasize on the importance of population level approaches to the prevention of cardiovascular diseases. Systematic global cardiovascular disease risk assessment is recommended in individuals with any major vascular risk factor. Regarding LDL-cholesterol, blood pressure, and glycemic control in patients with diabetes mellitus, goals and targets remain as recommended in previous guidelines. However, it is proposed a new, stepwise approach (steps 1 and 2) to treatment intensification as a tool to help physicians and patients pursue these targets in a way that fits patient profile. After step 1, considering proceeding to the intensified goals of step 2 is mandatory, and this intensification will be based on 10-year cardiovascular disease risk, lifetime cardiovascular disease risk and treatment benefit, comorbidities and patient preferences.</p><p>The updated SCORE algorithm ?SCORE2, SCORE2-OP? is recommended in these guidelines, which estimates an individual's 10-year risk of fatal and non-fatal cardiovascular disease events (myocardial infarction, stroke) in healthy men and women aged 40-89 years. Another new and important recommendation is the use of different categories of risk according to different age groups (<<!--> <!-->50, 50-69, ≥<!--> <!-->70 years).</p><p>Different flow charts of cardiovascular disease risk and risk factor treatment in apparently healthy persons, in patients with established atherosclerotic cardiovascular disease, and in diabetic patients are recommended. Patients with chronic kidney disease are considered high risk or very high-risk patients according to the levels of glomerular filtration rate and albumin-to-creatinine ratio. New lifestyle recommendations adapted to the ones published by the Spanish Ministry of Health as well as recommendations focused on the management of lipids, blood pressure, diabetes and chronic renal failure are included.</p></div>\",\"PeriodicalId\":45230,\"journal\":{\"name\":\"Clinica e Investigacion en Arteriosclerosis\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2022-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinica e Investigacion en Arteriosclerosis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0214916822000365\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica e Investigacion en Arteriosclerosis","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0214916822000365","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
摘要
我们提出了2021年欧洲心血管疾病预防临床实践指南的西班牙改编。目前的指南除了个人方法外,还非常强调人群水平方法对预防心血管疾病的重要性。建议对具有任何主要血管危险因素的个体进行系统的全球心血管疾病风险评估。关于糖尿病患者的低密度脂蛋白胆固醇、血压和血糖控制,目标和指标仍与先前指南中推荐的一样。然而,我们提出了一种新的、逐步的方法(步骤1和步骤2)来加强治疗,作为一种工具,帮助医生和患者以符合患者特征的方式追求这些目标。在第1步之后,必须考虑进入第2步的强化目标,这种强化将基于10年心血管疾病风险、终生心血管疾病风险和治疗获益、合并症和患者偏好。更新后的SCORE算法?SCORE2, SCORE2- op ?该指南估计40-89岁健康男性和女性10年发生致命性和非致命性心血管疾病事件(心肌梗死、中风)的风险。另一项新的重要建议是根据不同年龄组使用不同的风险分类(<50、50-69、≥70岁)。建议在表面健康的人、已确诊的动脉粥样硬化性心血管疾病患者和糖尿病患者中使用不同的心血管疾病危险和危险因素治疗流程图。根据肾小球滤过率和白蛋白/肌酐比值的水平,慢性肾病患者被认为是高危或高危患者。根据西班牙卫生部公布的新生活方式建议以及针对血脂、血压、糖尿病和慢性肾衰竭管理的建议进行了调整。
Comentario del CEIPV a las nuevas Guías Europeas de Prevención Cardiovascular 2021
We present the Spanish adaptation of the 2021 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. The current guidelines besides the individual approach greatly emphasize on the importance of population level approaches to the prevention of cardiovascular diseases. Systematic global cardiovascular disease risk assessment is recommended in individuals with any major vascular risk factor. Regarding LDL-cholesterol, blood pressure, and glycemic control in patients with diabetes mellitus, goals and targets remain as recommended in previous guidelines. However, it is proposed a new, stepwise approach (steps 1 and 2) to treatment intensification as a tool to help physicians and patients pursue these targets in a way that fits patient profile. After step 1, considering proceeding to the intensified goals of step 2 is mandatory, and this intensification will be based on 10-year cardiovascular disease risk, lifetime cardiovascular disease risk and treatment benefit, comorbidities and patient preferences.
The updated SCORE algorithm ?SCORE2, SCORE2-OP? is recommended in these guidelines, which estimates an individual's 10-year risk of fatal and non-fatal cardiovascular disease events (myocardial infarction, stroke) in healthy men and women aged 40-89 years. Another new and important recommendation is the use of different categories of risk according to different age groups (< 50, 50-69, ≥ 70 years).
Different flow charts of cardiovascular disease risk and risk factor treatment in apparently healthy persons, in patients with established atherosclerotic cardiovascular disease, and in diabetic patients are recommended. Patients with chronic kidney disease are considered high risk or very high-risk patients according to the levels of glomerular filtration rate and albumin-to-creatinine ratio. New lifestyle recommendations adapted to the ones published by the Spanish Ministry of Health as well as recommendations focused on the management of lipids, blood pressure, diabetes and chronic renal failure are included.
期刊介绍:
La publicación idónea para acceder tanto a los últimos originales de investigación como a formación médica continuada sobre la arteriosclerosis y su etiología, epidemiología, fisiopatología, diagnóstico y tratamiento. Además, es la publicación oficial de la Sociedad Española de Arteriosclerosis.